Expression of miRNA-26a in platelets is associated with clopidogrel resistance following coronary stenting

作者：Shuxia Chen, Xiaoyong Qi, Hua Chen, Mingquan Li, Jian Gu, Chunxia Liu, Hua Xue, Lili Wang, Yanping Geng, Qi Peng, Yuping Han · 发表于：Experimental and Therapeutic Medicine · 年份：2016 · DOI：10.3892/etm.2016.3278 · 被引用次数：22 · 研究领域：Coronary Interventions and Diagnostics、MicroRNA in disease regulation、Cancer-related molecular mechanisms research

The present study aimed to evaluate the association between platelet microRNA (miRNA)-26a expression and clopidogrel resistance in patients who underwent coronary stenting. Between September 2013 and August 2014, 43 patients with coronary heart disease underwent percutaneous coronary intervention at Heibei General Hospital (Shijiazhuang, China). In the same period, 20 healthy volunteers without any history of cardiovascular disease were enrolled in the present study as the control group. Flow cytometry was used to measure the phosphorylation levels of vasodilator-stimulated phosphoprotein (VASP), and to calculate the platelet reactivity index (PRI). Low response to clopidogrel was defined as PRI ≥50% on day 7 following clopidogrel administration. Western blotting was used to measure protein expression of VASP and reverse transcription-quantitative polymerase chain reaction analysis was performed to determine the expression levels of mRNA and miRNAs. Bioinformatics tools were employed to predict that miR-26a, miR-199 and miR-23a may target VASP mRNA. The results of the present study demonstrated that the activity of platelets in patients with low or high clopidogrel response was increased, as compared with healthy subjects. No differences in platelet VASP protein expression levels were detected between patients with high clopidogrel response and healthy subjects; whereas VASP protein expression was elevated in patients with low clopidogrel response. Furthermore VASP gene trans...